Penn Precision Medicine – Accelerator Fund Projects: Translating a Precision Medicine Approach for Treating IMCD into a Clinical Trial

In this personal consideration of the effects of mortal disease, David C. Fajgenbaum, MD, MBA, MSc, describes his experience with refractory idiopathic multi centric Castleman’s Disease (iMCD), an autoimmune disease that attacks and disables key organs in the body. A researcher as well as clinician, Dr. Fajgenbaum combined data analysis, research and experimentation at the Penn Center for Precision Medicine to define the role of the mTOR pathway in the autoimmunity of iMCD, and ultimately, to develop a treatment regimen for the disease. Dr. Fajgenbaum is a Research Assistant Professor of Medicine at Penn Medicine.

Related Links:
Castleman Disease Collaborative Network
Treatment Doctor Tested On Himself Can Put Others into Remission
Dr. Fajgenbaum’s Profile
View Upcoming Provider Events
Sign-up for Penn Medicine's Internal Newsletters


February 13, 2018

Created by

Penn Physician VideoLink